GO
Loading...

Pfizer Inc

More

  • Answers To Your Questions About The Sell-Off Monday, 5 Mar 2007 | 9:15 PM ET

    Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....

  • Cramer's Cure for a Market Hangover Wednesday, 28 Feb 2007 | 6:13 PM ET

    After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.

  • The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.

  • A Valentine For Onyx Tuesday, 13 Feb 2007 | 2:22 PM ET

    Onyx Pharmaceuticals is up big for the second day in a row. The stock nearly doubled yesterday on astronomical volume of 56,000,000 shares and today as I write this it's up almost 8% with more than 18,000,000 shares changing hands. So, what's up besides the stock?

  • Rethinking CEO Pay Thursday, 8 Feb 2007 | 9:42 AM ET

    What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The WEF meeting is tackling the issue by asking basic questions: What’s an appropriate level for top managers? Who defines “appropriate” and how?  Should a CEO’s pay be linked to the company’s performance? The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects. (More)

  • AstraZeneca To Ax 3,000; Blames Generics Friday, 2 Feb 2007 | 12:14 PM ET

    When Pfizer announced its deeper cost cuts last week, including a total of about 10,000 layoffs, analysts said other big drug companies that had not already started restructuring would use the industry giant as the model. Sure enough, today AstraZeneca said it will get rid of 3,000 employees (5% of its workforce) over the next few years. Also: Gilead shares at record high.

  • Eli Lilly Profit Falls 81%, But Tops Expectations Wednesday, 31 Jan 2007 | 12:00 PM ET

    The pharmaceutical company said fourth-quarter net income fell 81%, weighed down by liability and restructuring charges. However, excluding these items, Lilly's profits  outpaced analysts' expectations.

  • Exec Comp: Should Shareholders Hold Say? Friday, 26 Jan 2007 | 3:06 PM ET

    The days of Enron and WorldCom-sized corporate malfeasance scandals may seem like they just ended, but another debate regarding corporate ethics is reaching critical mass in boardrooms across the country – the issue of executive compensation. Adding fuel to the fire were the recent lucrative severance packages for Home Depot CEO Bob Nardelli ($210 million) and Pfizer  CEO Hank McKinnell...

  • Rethinking CEO Pay Thursday, 25 Jan 2007 | 4:17 PM ET

    What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The WEF meeting is tackling the issue by asking basic questions: What’s an appropriate level for top managers? Who defines “appropriate” and how?  Should a CEO’s pay be linked to the company’s performance? The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects. (More)

  • Stocks Finish Higher Amid Earnings Flurry, Rising Oil Tuesday, 23 Jan 2007 | 5:02 PM ET

    Stocks ended the day higher as investors evaluated a mixed batch of quarterly earnings reports and energy stocks moved higher on a spike in oil prices.

  • Layoffs a Bitter Pill for Employees and Investors Tuesday, 23 Jan 2007 | 1:31 PM ET

    As I write this Pfizer shares are down about 2.5% in intra-day trading on top of the 1% loss yesterday.  Usually investors cheer when a company announces substantial cost cuts--10,000 jobs, as many as eight facility closures or sales, $1.5 billion-$2 billion in savings by the end of '08. Yesterday you could argue the move was simple selling on the news as the layoffs and cost cuts had been leaked a week ahead of the meeting.  But today ...

  • Johnson & Johnson Profit Rises on Higher Drug Sales Tuesday, 23 Jan 2007 | 12:10 PM ET

    The diversified health-care company earned $2.17 billion, or 74 cents a share in the fourth quarter, compared with $2.1 billion, or 70 cents, a year earlier.

  • More Tech Angst And Earnings Obsessions Tuesday, 23 Jan 2007 | 8:17 AM ET

    Stocks in the U.S. for now look headed to open flat to lower-- after yesterday's rocky trading. Europe is moving lower and oil is getting a lift from cold weather. Some big companies will roll out earnings reports today, to a market that has become hypersensitive to corporate earnings growth. Bank America, Johnson & Johnson and DuPont all report today.

  • Stocks ended sharply lower after a day long selling spree, sparked by worries corporate earnings growth is showing signs of weakening.

  • Pfizer to Slash 10,000 Jobs in Cost-Cutting Move Monday, 22 Jan 2007 | 2:06 PM ET

    Pfizer also provided per-share earnings guidance for 2007 in the range of $2.18 to $2.25, which would represent growth of between 6% and 9%. A Thomson Financial consensus estimate puts the company's earnings at $2.19 for the year.

  • The drugmaker earned $9.45 billion in the fourth quarter, or $1.32 a share, compared with $2.73 billion, or 37 cents a share, a year earlier.

  • A Mix of Oil, World Politics And Global Warming Monday, 22 Jan 2007 | 8:33 AM ET

    Stocks in the U.S. are leaning towards a higher open, as investors brace for a barrage of earnings news. Oil is bucking its recent downtrend and is slightly higher as cold weather finally settles into the Northeast. European stocks are trading higher, helped by mining, metals and oil stocks. Asian markets closed higher with Tokyo at a 9-month high.

  • Potent Growth in Impotence Drug Market Friday, 19 Jan 2007 | 12:51 PM ET

    The Eli Lilly-Icos joint venture reported that worldwide sales of their erectile dysfunction drug came to $971 million last year -- and is now on the cusp of becoming a billion-dollar blockbuster drug in 2007.  We will find out how Viagra is doing when Pfizer reports earnings before the bell on Monday morning, but sales growth is expected to have picked up.  These results represent a significant turnaround in a drug segment that some thought had already had its day.

  • Pfizer Expected to Cut Staff as Part of Overhaul Friday, 19 Jan 2007 | 11:55 AM ET

    Pfizer may announce $2 billion in cost cuts including plant closings and slashing up to 10% of the work force when new chairman and CEO Jeffrey Kindler announces his plan next week for a strategic overhaul of the world's largest drugmaker, analysts say.

  • Jan. 22: Two, Too Much to Cover Wednesday, 17 Jan 2007 | 1:54 PM ET

    As we get into the thick of earnings season, next Monday is shaping up to be a big news day for big pharma. Before the bell Pfizer will put out its press release with its 2006 and fourth-quarter numbers.  Then, at 1 p.m. ET the company is holding an analyst meeting in midtown Manhattan where "The Wall Street Journal" reports Pfizer will announce more job cuts and other changes in the way it does business  ...  Meantime, in lower Manhattan the patent trial over Bristol-Myers Squibb's blockbuster bloodthinner Plavix gets underway on Monday morning ... And, finally, opening arguments are set for Monday morning in the two-in-one Vioxx trial in Atlantic City ...

Most Popular Video

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.